This highlights the need for simultaneous inhibition of RET, EGFR, and VEGFR in certain tumor types.23 Since there are no better therapeutic options after selective RET inhibitors resistance and considering that Vandetanib and Lenvatinib inhibit EGFR- and VEGFR- dependent signaling, simultaneously RET receptor tyrosine kinase, which are all important growth drivers in NSCLC. This evidence concerns the gene KDR and non-small cell lung carcinoma.